Charles M. Rice

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

166h-index100.5kcitations719works6.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(276), Hepatitis B Virus Studies(191), Mosquito-borne diseases and control(110), Liver Disease Diagnosis and Treatment(91), interferon and immune responses(84)

Publications707 total

890 Intravesical recombinant MVA therapy induces local and systemic antitumor immunity and memory in an orthotopic murine bladder cancer model
Regular and Young Investigator Award Abstracts·2025Open Access
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
UNC Libraries·2025Open Access
An immunocompetent murine model of virus-elicited liver fibrosis and hepatocellular carcinoma
2025Open Access
Discovery, Optimization, and Evaluation of Non-Nucleoside SARS-CoV-2 NSP14 Inhibitors
Journal of Medicinal Chemistry·2025· 1 citedOpen Access
Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts
2025Open Access
Discovery of Novel Isofunctional SARS-CoV-2 NSP14 RNA Cap Methyltransferase Inhibitors by Structure-Based Virtual Screening
ACS Medicinal Chemistry Letters·2025Open Access
Engineered bacteria launch and control an oncolytic virus
Nature Biomedical Engineering·2025· 7 citedOpen Access
An enhanced Eco1 retron editor enables precision genome engineering in human cells without double-strand breaks
Nucleic Acids Research·2025· 2 citedOpen Access
Pan-viral ORFs discovery using massively parallel ribosome profiling
Science·2025· 1 citedOpen Access
FRI-262-YI Isogenic studies of basal-core promoter and precore mutations in hepatitis B genotype c
Journal of Hepatology·2025
Abstract 3280: Type I IFN receptor signaling in myeloid and T cells drives antitumor immunity elicited by intratumoral delivery of immunogenic recombinant modified vaccinia virus Ankara
Cancer Research·2025
Mitochondrial hyperactivity and reactive oxygen species drive innate immunity to the yellow fever virus-17D live-attenuated vaccine
PLoS Pathogens·2025· 4 citedOpen Access
Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains
The Journal of Experimental Medicine·2025· 7 citedOpen Access
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed
Nature Reviews Gastroenterology & Hepatology·2025· 5 cited
Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice
UNC Libraries·2025Open Access
A DNA launch method for HBV infection in human hepatocyte chimeric mice enables isogenic studies of basal-core promoter and precore mutants
Zeitschrift für Gastroenterologie·2025
Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase
Nature·2024· 35 cited
Repurposing of lonafarnib as a treatment for SARS-CoV-2 infection
JCI Insight·2024· 1 citedOpen Access
Distinct pathways for evolution of enhanced receptor binding and cell entry in SARS-like bat coronaviruses
PLoS Pathogens·2024· 9 citedOpen Access
Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease
The Journal of Experimental Medicine·2024· 20 citedOpen Access
page 1 of 36Next →

Frequent Co-authors

Paul D. Bieniasz(8), Hans-Heinrich Hoffmann(7), Jane A. McKeating(7), Théodora Hatziioannou(7), Eleftherios Michailidis(6), Michel C. Nussenzweig(6), Brett D. Lindenbach(6), John W. Schoggins(5), Christian Gaebler(5), Frauke Muecksch(5), Zijun Wang(5), Anna Gazumyan(5), Melissa Cipolla(5), Marina Caskey(5), Arash Grakoui(5), S M Feinstone(5), Maryline Panis(4), Davide F. Robbiani(4), Alice Cho(4), Fabian Schmidt(4)